Increased expression of methionine sulfoxide reductases�B3 is associated with poor prognosis in gastric cancer

Abstract

The present study aimed to investigate the expression of methionine sulfoxide reductases B3 (MSRB3) in gastric cancer (GC) and its clinical significance. A total of 90 specimens from patients with GC were collected to evaluate MSRB3 protein expression by immunohistochemical staining. The associations between MSRB3 protein expression, clinicopathological characteristics and prognosis of patients with GC were subsequently investigated. The results demonstrated that MSRB3 protein expression in GC tissues samples was significantly higher compared with that in paired adjacent normal tissues (P=0.017). Among the 90 GC cases, 64 (71.1%) exhibited higher MSRB3 expression. In addition, the diagnostic value of MSRB3 for patients with GC was estimated with a sensitivity of 71.1% and a specificity of 46.7%. However, MSRB3 expression was not associated with clinicopathological characteristics of patients with GC. Kaplan-Meier analysis indicated that patients with high MSRB3 expression had significantly shorter overall survival (OS) times compared with those with low expression (P=0.040). Univariate Cox regression analysis indicated that maximum tumor diameter, depth of invasion, lymph node metastasis, Tumor-Node-Metastasis (TNM) stage and MSRB3 expression were significantly associated with OS time. Multivariate Cox regression analysis indicated that MSRB3 was an independent predicting factor for the OS time of patients with GC (P=0.049). In addition, analysis using The Cancer Genome Atlas (TCGA) database validated these results. Kaplan-Meier analysis revealed that higher MSRB3 mRNA expression was associated with poorer OS time in 442 patients with GC (P=0.004). Univariate analysis of the TCGA data indicated that age, depth of invasion, lymph node metastasis, distant metastasis, TNM stage and MSRB3 expression were significantly associated with OS time; however, sex and histological differentiation were not associated with OS time. Multivariate analysis demonstrated that MSRB3 was an independent prognostic factor in patients with GC (P=0.001). In conclusion, these results demonstrated that MSRB3 expression was upregulated in patients GC, which suggests that MSBR3 may serve as a potential prognostic biomarker.

Genome-Wide Identification and Characterization of DNA Methylation and Long Non-Coding RNA Expression in Gastric Cancer

“…GO analysis revealed that these lncRNAs were involved in dysregulated transcriptional programs that invariably lead to cancer. We also found that predicted mRNAs HOXC10 and MSRB3 in GO analysis were significantly associated with overall survival in GC patients (Kim et al, 2019;Ma et al, 2019).…”

A Combined Systemic Strategy for Overcoming Cisplatin Resistance in Head and Neck Cancer: From Target Identification to Drug Discovery

“…For those molecules that were demonstrated to be correlated with poor prognosis in HNC patients ( Figure 4 C), RHEB was also found overexpressed in prostate cancer, associated with poor prognosis [ 34 ], and promoted cell growth via the regulation of the mTOR signaling pathway [ 35 , 36 ]. Elevated expression of MSRB3 (methionine sulfoxide reductase), a reactive oxygen species scavenging enzyme, was shown to be associated with poorer survival in gastric cancer [ 37 , 38 ]. The ULBP1 (UL16 binding protein 1), known as a “stress-induced ligand”, was upregulated in cancer cells and related to the function of escaping immune surveillance [ 39 ].…”

Integrative analysis of exosomal microRNA-149-5p in lung adenocarcinoma

“…In breast cancer, deficiency of MSRB3 promoted tumor cells apoptosis via the intrinsic mitochondrial apoptosis pathway [27], p53-independent and ER stress-dependent pathways [28]. In addition, MSRB3 was significantly downregulated in gastric cancer and it predicted poor prognosis [29]. On the other hand, up-regulation of MSRB3 accelerated renal cell carcinoma cells metastasis [30].…”